MedTrace Logo

18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma

NCT06813742 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-08-07

No results posted yet for this study

Summary

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.

Conditions

  • Pheochromocytoma

Interventions

DRUG

18F-MFBG

Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-12-05
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06813742 on ClinicalTrials.gov